Home Search Contacts Help
ABPI - The Association of the British Pharmaceutical Industry
 
Target Diabetes

Marketed and experimental medicines for the treatment of diabetes in the UK
 

Company Product name
/number		 Product
type		 Phase of development Status and comment
(October 1998)
PC I II III L
Amgen Filgrastim-G-CSF Growth factor May speed healing of diabetic foot infections
Amylin Pramlintide Peptide hormone related to amylin   Filing anticipated for mid-1999

AC2993
(Exendin-4)

 Peptide hormone       Distantly related to GLP-1 but with some distinct properties
Bayer Acarbose Alph-glucosidase inhibitor  
Bristol-Myers Squibb Captopril Early ACE inhibitor For renal complications of diabetes
Fosinopril Second generation ACE inhibitor For renal complications of diabetes
Cortecs Macrulin Oral insulin      
CP Pharmaceuticals Insulins Various forms Launched forms include soluble, isophane and zinc insulins

Genentech/Roche

 Pimagedine AGE-inhibitor   For secondary complications of diabetes Phase III in USA
Glaxo Wellcome GI-262570 Gamma receptor antagonist     Phase II reults awaited Spring 1999 in Type 2 diabetes
Troglitazone 'Glitazone' Marketed in USA by Parke-Davis / Waner Lambert
Hoechst Marion Roussel Glibenclamide Sulphonylurea  
Tolbutamide Sulphonylurea The first of this class to be launched in 1956
HOE 901 Human insulin   Long-acting 'basal' insulin
Eli Lilly and Company Insulin Various forms Several, including neutral, biphasic, zinc and isophane forms
Insulin Lispro Short-acting form A genetically engineered insulin launched in 1996
Glucagon Pancreatic peptide Used for severe hypoglcaemics attacks
Merck Metformin Biguanide  
Novartis Apligof Synthetic skin   To accelerate healing of diabetic ulcers
Navo Nordisk Insulins Various forms Several, including neutral, biphasic, zinc and isophane forms
  Insulin Aspart Insulin analogue   Short-acting insulin analogue
  NN-304 Insulin coupled to fatty acyl grout     Novel form of long-acting insulin for Types 1 and 2 diabetes
  Repaginide Stmulator of insulin secretion Mealtime glucose regulator for Type 2 diabetes
  GLP-1-like peptide Injectable peptide       Glucagon-like peptide that stimulates insulin secretion
  NNC-05-1869         Forsecondary neuropathic complications
  Glucagen Pancreatic Peptide For control of hypoglycaemic attacks
Parke-Davis Warner Lambert Zenarestat Aldose reductase inhibator Phase III trials due to begin in Spring 1999
Pfizer Glipizide Sulphonyurea  
  Pulmonary Insulin Inhalation form of insulin       Co-development with Inhale Therapeutics
  Zopolrestat Aldose reductase inhibitor   For diebetic complications such as neurpathy
Pharmacia & Upjohn Glipizide Sulphonylurea  
  Tolazamide Sulphonylurea  
Sonofi Winthrop Gliquidone Sulphonylurea  
  Miglitol Alpha-glucoisdase   Launch imminent
Servier Gliclazide Sulphonylurea  
Schwarz Pharma C-peptide analogues Cleavage product of proinsulin       May help control secondary complications
Smith & Nephew Dermagraft Synthetic skin To accelerate healing of diebetic ulcers. Launched 1998
SmithKlein Beecham Rosiglitazone 'Glitazone'   For insulin-resistant NDDM
Takeda Voglibose Alpha-glucosidase inhibitor  
  Pioglitazone 'Glitazone   For insulin-resistant NDDM
Wyeth Lederle Minalrestat Aldose redutase inhibitor    
Yamanouchi YM 440 'Glitazone'      
Zeneca Lisinopril Second generation Ace inhibitor For renal complications of diabetes

< Previous Page | Contents | Next Page >

 
PC, I, II, III = Preclinical and Phase I, II and III clinical trials;
L = Licensed;







 
 
Previous Page | Print Page | Top of Page
Copyright © ABPI - The Association of the British Pharmaceutical Industry Terms and Conditions | Privacy Policy